International Journal of Hematology-Oncology and Stem Cell Research 2017. 11(4):262-267.

Effect of Short Hydration on Cisplatin-Induced Nephrotoxicity in Cancer Patients: A Retrospective Study
Farzaneh Ashrafi, Zeinab Ebrahimi, Mehdi Nematbakhsh


Background: The aim of this study was to evaluate the protective role of short hydration against nephrotoxicity induced by cisplatin (CDDP).

Materials and Methods: Twenty-two patients (13 men and 9 women) under CDDP therapy were enrolled in this retrospective study between 2009 and 2014. The CDDP was given in 500 ml of isotonic solution, and before and after CDDP administration, the patients received 10mEq potassium chloride15% and 1gr magnesium sulfate in 1000 ml isotonic saline. Renal parameters were evaluated on the first day of each cycle of CDDP therapy.

Results: Median cumulative CDDP dose was 465 mg/m2. Based on renal parameters, the prevalence of CDDP-induced nephrotoxicity (CIN) was 22.7%, while no hypokalemia and hypomagnesemia were observed.

Conclusion:  Short hydration accompanied with potassium chloride and magnesium sulfate may decrease the risk of CIN.



Cisplatin, Nephrotoxicity, Hydration, Magnesium, Potassium

Full Text:



Tezcan S, Izzettin FV, Sancar M, et al. Nephrotoxicity evaluation in outpatients treated with cisplatin-based chemotherapy using a short hydration method. Pharmacology & Pharmacy. 2013;4(3):296.

Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008; 73(9):994-1007

Antunes LM, Darin JD, Bianchi MD. Protective effects of vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependent study. Pharmacol Res. 2000; 41(4):405-11.

Miller RP, Tadagavadi RK, Ramesh G, et al. Mechanisms of cisplatin nephrotoxicity. Toxins (Basel). 2010; 2(11): 2490–2518.

dos Santos NA, Carvalho Rodrigues MA, Martins NM. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol. 2012; 86(8):1233-50.

Moon HH, Seo KW, Yoon KY, et al. Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients. World J Gastroenterol. 2011; 17(30):3510-7.

Florea AM, Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel). 2011; 3(1):1351-71.

Tezcan S, Izzettin FV, Sancar M, et al. Nephrotoxicity Evaluation in Outpatients Treated with Cisplatin-Based Chemotherapy Using a Short Hydration Method. Pharmacology & Pharmacy. 2013; 4(3): 296-302.

Yamada K, Yoshida T, Zaizen Y, et al. Clinical practice in management of hydration for lung cancer patients receiving cisplatin-based chemotherapy in Japan: a questionnaire survey. Jpn J Clin Oncol. 2011; 41(11):1308-11

Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int. 2014; 2014:967826.

Yao X, Panichpisal K, Kurtzman N, et al. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007; 334(2):115-24.

Muraki K, Koyama R, Honma Y, et al. Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer. J Thorac Dis. 2012; 4(6):562-8.

Sanchez-Gonzalez PD, Lopez-Hernandez FJ, Perez-Barriocanal F, et al. Quercetin reduces cisplatin nephrotoxicity in rats without compromising its anti-tumour activity. Nephrol Dial Transplant. 2011; 26(11):3484-95

Prasaja Y, Sutandyo N, Andrajati R. Incidence of Cisplatin-Induced Nephrotoxicity and Associated Factors among Cancer Patients in Indonesia. Asian Pac J Cancer Prev. 2015; 16(3):1117-22.

Ouchi A, Asano M, Aono K, et al. Comparison of short and continuous hydration regimen in chemotherapy containing intermediate-to high-dose Cisplatin. J Oncol. 2014; 2014:767652.

Horinouchi H, Kubota K, Itani H, et al. Short hydration in chemotherapy containing cisplatin (≥ 75 mg/m2) for patients with lung cancer: a prospective study. Jpn J Clin Oncol. 2013; 43(11):1105-9,

Montoya J, Luna HG, Amparo JR, et al. Renal function of cancer patients" fit" for Cisplatin chemotherapy: physician perspective. Gulf J Oncolog. 2014; 1(16):64-72.

Health UDo, Services H. Common terminology criteria for adverse events (CTCAE) version 4.0. National Institutes of Health, National Cancer Institute. 2009;4(03).

Haim N, Oman SD, Galai N, et al. Estimation of creatinine clearance without 24-hour urine collection—a useful guide during cisplatin therapy. Acta Oncol. 1993;32(4):409-12.

Jang HJ, Cho JW, Park B, et al. The Assessment of Tumor Response by Measuring the Single Largest Lesion per Organ in Metastatic Tumors: A Pooled Analysis of Previously Reported Data. J Cancer. 2015; 6(2):169-76.

Ashrafi F, Nematbakhsh M, Safari T, et al. A combination of vitamin C and losartan for cisplatin-induced nephrotoxicity in rats. Iran J Kidney Dis. 2012; 6(5):361-5.

Nematbakhsh M, Pezeshki Z. Sex-related difference in nitric oxide metabolites levels after nephroprotectant supplementation administration against cisplatin-induced nephrotoxicity in Wistar rat model: the role of vitamin E, erythropoietin, or N-Acetylcysteine. ISRN Nephrol. 2013; 2013: 612675.

Muraki K, Koyama R, Honma Y, et al. Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer. J Thorac Dis. 2012; 4(6):562-8.

Beladi Mousavi SS, Hossainzadeh M, Khanzadeh A, et al. Protective Effect of Forced Hydration with Isotonic Saline, Potassium Chloride and Magnesium Sulfate on Cisplatin Nephrotoxicity: An Initial Evaluation. Asia Pacific Journal of Medical Toxicology. 2013; 2(4):136-139.

Yoshida T, Niho S, Toda M, et al. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study. Jpn J Clin Oncol. 2014; 44(4):346-54.

Kidera Y, Kawakami H, Sakiyama T, et al. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS One. 2014; 9(7):e101902.

Nematbakhsh M, Talebi A, Nasri H, et al. Some evidence for sex-based differences in cisplatin-induced nephrotoxicity in rats. Med Sci Tech. 2012; 53(1): RA29-32

Nematbakhsh M, Ebrahimian S, Tooyserkani M, et al. Gender difference in Cisplatin-induced nephrotoxicity in a rat model: greater intensity of damage in male than female. Nephrourol Mon. 2013; 5(3):818-21.

Nematbakhsh M, Ghadesi M, Hosseinbalam M, et al. Oestrogen promotes coronary angiogenesis even under normoxic conditions. Basic Clin Pharmacol Toxicol. 2008; 103(3):273-7.

Nematbakhsh M, Pezeshki Z, Eshraghi-Jazi F, et al. Vitamin E, vitamin C, or losartan is not nephroprotectant against cisplatin-induced nephrotoxicity in presence of estrogen in ovariectomized rat model. Int J Nephrol. 2012; 2012: 284896.

Pezeshki Z, Nematbakhsh M, Nasri H, et al. Evidence against protective role of sex hormone estrogen in Cisplatin-induced nephrotoxicity in ovarectomized rat model. Toxicol Int. 2013; 20(1): 43–47.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.